Two new studies jointly published in Nature: The Clinical Microbiome reveal that certain species of fungi in the gut play a key role in the development of immune dysregulation and some pediatric allergic diseases — and may […]
As oral drug delivery moves beyond the small intestine, ileocolonic targeting is emerging as a key enabler for next‑generation therapeutics. This article explores how colonic delivery technologies – including pH‑dependent polymers, multi‑trigger coatings and ready‑to‑fill […]
Researchers at the Icahn School of Medicine at Mount Sinai have developed a new manufacturing platform for producing targeted mixtures of beneficial gut bacteria, an approach that could help expand access to microbiome-based therapies for […]
The global probiotics market has experienced sustained and rapid growth over the past decade, driven by increasing consumer awareness of gut health, immunity, and the central role of the microbiome in overall well‑being. Discussions at […]
Gut microbiome research has changed. Many studies no longer stop at identifying which microbes are present. They are now also looking at what those microbes are doing, often by measuring the metabolites they produce or […]
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that all primary and secondary objectives were met in its advanced melanoma (MELODY-1) Phase 1b trial. […]
Kanvas Biosciences, a full-stack spatial biology company, today announced it has raised a $48 million Series A funding round co-led by existing investors DCVC and Lions Capital LLC. Additional participating investors include Gates Foundation, ATHOS […]
When the liver fails, toxins – such as ammonia – that should be filtered from the blood build up and reach the brain. The result is hepatic encephalopathy (HE), a devastating neurological complication of liver […]
Bacterial vaginosis (BV) is one of the most common vaginal conditions affecting women of reproductive age worldwide, with prevalence rates estimated between 15% and 50%. It is a condition characterized by a disruption of the […]
EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in-class microbiome therapies for gut health, today announces the completion of a £19m ($25m) financing to advance its lead candidate, EBX-102-02, a next-generation orally delivered full-spectrum investigational microbiome […]
mbiomics GmbH, a pioneering techbio company advancing scalable microbiome-based therapeutics for severe and chronic diseases, today announced the successful third closing of its Series A round at €12 million, bringing the total round size to […]